Niagen Bioscience Partners with Truemed for HSA/FSA Purchases

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Jan 15 2026

0mins

Niagen Bioscience announced it has partnered with Truemed to allow qualified customers to purchase Tru Niagen using health savings account and flexible spending account funds on its website. Customers can use these funds with a Truemed letter of medical necessity issued by a licensed provider. "Truemed exists to make preventive health tools more financially accessible," said Justin Mares, co-founder and CEO of Truemed. "We are excited to help qualified customers use HSA/FSA funds to support their healthspan with Tru Niagen."

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy NAGE?" and start using high-conviction signals backed by rigorous historical data.

NAGE

$6.03+Infinity%1D

Analyst Views on NAGE

Wall Street analysts forecast NAGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAGE is 16.33 USD with a low forecast of 12.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 6.240

Low

12.00

Averages

16.33

High

23.00

Current: 6.240

Low

12.00

Averages

16.33

High

23.00

Canaccord

Buy

downgrade

$16 -> $14

2025-11-05

Reason

Canaccord

Price Target

$16 -> $14

AI Analysis

2025-11-05

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Niagen Bioscience to $14 from $16 and keeps a Buy rating on the shares. The firm said they posted a Q3 beat as they continue to see strong demand for the flagship TruNiagen supplement businesses, leading to total company sales up +32.9% vs. our/Street estimate of +22.6%/+22.0%.

H.C. Wainwright

Buy

maintain

$11 -> $12

2025-08-11

Reason

H.C. Wainwright

Price Target

$11 -> $12

2025-08-11

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Niagen Bioscience to $12 from $11 and keeps a Buy rating on the shares. The company's Q2 revenue and earnings beat expectations, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NAGE

Unlock Now

About NAGE

Niagen Bioscience, Inc. specializes in nicotinamide adenine dinucleotide (NAD+) science and healthy-aging research. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NAGE?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NAGE?

Get Started Free

Top News

Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market

Jan 21 2026Newsfilter

Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000, marking a strategic expansion into the performance wellness segment, which is expected to accelerate the Canadian launch of next-generation clean energy pouches.
Executive Appointment: Concurrently, the company appointed Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units, aiming to leverage his extensive experience in retail and brand building to drive business growth.
Market Potential: According to Grand View Research, the global energy drinks market is projected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, while the nicotine pouch category is expected to expand from $5.4 billion to over $25 billion at a 29.6% CAGR, indicating strong growth potential for Doseology's market positioning.
Product Innovation: Doseology's U.S. subsidiary is developing pouch-based offerings that blend caffeine, nootropics, and adaptogens, designed to provide sugar-free, smoke-free alternatives for professionals and wellness consumers seeking functional stimulation, further solidifying its competitive edge in the health tech sector.

an image of Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market

Niagen Bioscience Introduces Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. with Patented Niagen® (Nicotinamide Riboside)

Nov 13 2025Newsfilter

Launch of Tru Niagen® Beauty: Niagen Bioscience has introduced Tru Niagen® Beauty, the first beauty supplement in the U.S. featuring Niagen (nicotinamide riboside), aimed at enhancing skin, hair, and nail health through cellular support.
Key Ingredients and Benefits: The supplement contains a blend of clinically studied ingredients, including Astaxanthin, Hyaluronic Acid, Grape Seed Extract, Biotin, and Vitamin E, designed to improve skin hydration, elasticity, and overall beauty from within.
Market Growth Potential: The U.S. astaxanthin market is projected to grow significantly, reflecting increasing consumer demand for natural antioxidants and health supplements, while the global nutricosmetics market is also expected to expand rapidly.
Commitment to Scientific Research: Niagen Bioscience emphasizes its dedication to advancing healthspan through evidence-based innovations and rigorous scientific research, positioning itself as a leader in NAD+ science and healthy aging.

an image of Niagen Bioscience Introduces Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. with Patented Niagen® (Nicotinamide Riboside)

Niagen Bioscience Partners with Truemed for HSA/FSA Purchases

Trade with 70% Backtested Accuracy

Analyst Views on NAGE

About NAGE

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Society Pass Invests in Gorilla Networks to Expand eSIM Market

Docebo Approves $60 Million Share Buyback Plan

Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market

Niagen Bioscience Introduces Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. with Patented Niagen® (Nicotinamide Riboside)

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch